Oxaliplatin and axonal Na+ channel function in vivo

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4481-4484

  Krishnan, Arun V ^a,b   Goldstein, David ^a   Friedlander, Michael ^a   Kiernan, Matthew C ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; SODIUM CHANNEL;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; IN VIVO STUDY; NERVE CONDUCTION; NERVE CONDUCTION DISORDER; NERVE EXCITABILITY; NEUROPATHY; NEUROTOXICITY; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFLEX DISORDER; REFRACTORY PERIOD; SENSORY DYSFUNCTION;

ADULT; AXONS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SODIUM CHANNELS; TREATMENT OUTCOME;

EID: 33748083678     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0694     Document Type: Article

References (27)

1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
2. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plusleucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
3. McKeage MJ, Hsu T, Screnci D, et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001;85:1219-25.
4. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002;29:11-20.
5. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30:5-13.
6. Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25:13-22.
7. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60.
8. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
9. Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000;406:25-32.
10. Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;29:21-33.
11. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-7.
12. Krishnan AV, Lin CS-Y, Kiernan MC. Nerve excitability properties in lower limb motor axons: evidence for a length-dependent gradient. Muscle Nerve 2004;29:645-55.
13. Kiernan MC, Burke D, Andersen KV, et al. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000;23:399-409.
14. Kiernan MC, Lin CS, Andersen KV, et al. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001;24:883-92.
15. Kiernan MC, Isbister GK, Lin CS, et al. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 2005;57:339-48.
16. Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005;128:1178-87.
17. Kiernan MC, Krishnan AV, Lin CS, et al. Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain 2005;128:1841-6.
18. Kimura J. Electrodiagnosis in diseases of nerve and muscle. Philadelphia: FA Davis: 1983.
19. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol (Lond) 1952;117:500-44.
20. Kiernan MC, Cikurel K, Bostock H. Effects of temperature on the excitability properties of human motor axons. Brain 2001;124:816-25.
21. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11:509-13.
22. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055-61.
23. Craner MJ, Hains BC, Lo AC, et al. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 2004;127:294-303.
24. Steffensen I, Waxman SG, Mills L, et al. Immunolocalization of the Na(+)-Ca2+ exchanger in mammalian myelinated axons. Brain Res 1997;776:1-9.
25. Mogyoros I, Bostock H, Burke D. Mechanisms of paresthesias arising from healthy axons. Muscle Nerve 2000;23:310-20.
26. Cassidy J, Bjarnason GA, Hickish T, et al. Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU/LV combination (FOLFOX4) in first line treatment of patients with metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium 2006. [Abstract 229].
27. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;4:394-400.